BLUE News and Press, bluebird bio Inc. From 03/04/22

- The Company’s first two gene therapies, beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, under review by the FDA - - lovo-cel BLA submission for sickle cell disease remains on track for Q1 2023 - - Ended year with $442M in r...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

Gainers: Clover Health Investments CLOV +21%. WM Technology MAPS +14%. bluebird bio (NASDAQ:BLUE) +7%. STAAR Surgical Company STAA +7%. MannKind Corporation MNKD +6%. Losers: Rent-A-Center  RCII -31%. Pulmonx Corporation LUNG -20%. Five9 FIVN ...

Bluebird Bio is nearing approval of three potentially curative treatments for severe genetic diseases, although approval has been continually delayed. They recently left Europe over pricing disagreements, meaning they must convince US payors of the value of their expensive treatments,...

Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time. Let's address the second part of this stra...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I a...

FDA PDUFA goal dates for both therapies extended by three months bluebird bio, Inc . (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for its lentiviral vector gene...

Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) fell by 10.7% through the first four full days of trading this week, according to data provided by S&P Global Market Intelligence . Bluebird's shares hit the skids last Tuesday immediately after the company provi...

bluebird bio, Inc . (Nasdaq: BLUE) today announced planned updates to be presented at the 40 th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook. In 2022, bluebird is focused on the FDA review of two gene therapies –...

bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference, Wednesday, January 12, at 3:45 p.m. ET. To access the live webcast of bluebird bio’s presentation, pl...